Agenus Inc (AGEN) stock
AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.29−0.44 (-6.54%)
Close on Nov 16, 2026Market cap $283.18MP/E –Yield –
Agenus total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Agenus's total debt was $30.07M at Jun 30, 2026. For fiscal 2025 it was $44.66M, up 34.6% from the year before. Over ten years it grew -9.0% a year on average. The highest annual figure on record is $163.02M in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.66M | +34.6% |
| FY2024 | Dec 31, 2024 | $33.17M | +156.9% |
| FY2023 | Dec 31, 2023 | $12.91M | -1.9% |
| FY2022 | Dec 31, 2022 | $13.16M | -2.9% |
| FY2021 | Dec 31, 2021 | $13.55M | -31.3% |
| FY2020 | Dec 31, 2020 | $19.71M | +40.5% |
| FY2019 | Dec 31, 2019 | $14.03M | +5.0% |
| FY2018 | Dec 31, 2018 | $13.36M | -91.8% |
| FY2017 | Dec 31, 2017 | $163.02M | +24.7% |
| FY2016 | Dec 31, 2016 | $130.69M | +14.2% |
| FY2015 | Dec 31, 2015 | $114.47M | +1799.5% |
| FY2014 | Dec 31, 2014 | $6.03M | +71.3% |
| FY2013 | Dec 31, 2013 | $3.52M | +1624.0% |
| FY2012 | Dec 31, 2012 | $204.09K | +3.2% |
| FY2011 | Dec 31, 2011 | $197.68K | +35.3% |
| FY2010 | Dec 31, 2010 | $146.06K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.07M | -11.2% |
| Q1 FY2026 | Mar 31, 2026 | $30.19M | -10.1% |
| Q4 FY2025 | Dec 31, 2025 | $44.66M | +34.6% |
| Q3 FY2025 | Sep 30, 2025 | $34.21M | +155.3% |
| Q2 FY2025 | Jun 30, 2025 | $33.87M | +152.3% |
| Q1 FY2025 | Mar 31, 2025 | $33.58M | +147.3% |
| Q4 FY2024 | Dec 31, 2024 | $33.17M | +156.9% |
| Q3 FY2024 | Sep 30, 2024 | $13.40M | +2.2% |
| Q2 FY2024 | Jun 30, 2024 | $13.43M | +1.0% |
| Q1 FY2024 | Mar 31, 2024 | $13.58M | -0.5% |
| Q4 FY2023 | Dec 31, 2023 | $12.91M | -1.9% |
| Q3 FY2023 | Sep 30, 2023 | $13.11M | -2.6% |
| Q2 FY2023 | Jun 30, 2023 | $13.30M | -2.9% |
| Q1 FY2023 | Mar 31, 2023 | $13.65M | -3.8% |
| Q4 FY2022 | Dec 31, 2022 | $13.16M | -2.9% |
| Q3 FY2022 | Sep 30, 2022 | $13.46M | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $13.70M | -30.8% |
| Q1 FY2022 | Mar 31, 2022 | $14.18M | -30.4% |
| Q4 FY2021 | Dec 31, 2021 | $13.55M | -31.3% |
| Q3 FY2021 | Sep 30, 2021 | $13.33M | -33.4% |
| Q2 FY2021 | Jun 30, 2021 | $19.79M | -2.8% |
| Q1 FY2021 | Mar 31, 2021 | $20.38M | +54.0% |
| Q4 FY2020 | Dec 31, 2020 | $19.71M | +40.5% |
| Q3 FY2020 | Sep 30, 2020 | $20.03M | +44.6% |
| Q2 FY2020 | Jun 30, 2020 | $20.35M | +48.7% |
| Q1 FY2020 | Mar 31, 2020 | $13.23M | -2.1% |
| Q4 FY2019 | Dec 31, 2019 | $14.03M | +5.0% |
| Q3 FY2019 | Sep 30, 2019 | $13.85M | +4.9% |
| Q2 FY2019 | Jun 30, 2019 | $13.68M | +4.8% |
| Q1 FY2019 | Mar 31, 2019 | $13.52M | +4.7% |
| Q4 FY2018 | Dec 31, 2018 | $13.36M | -91.8% |
| Q3 FY2018 | Sep 30, 2018 | $13.20M | -90.8% |
| Q2 FY2018 | Jun 30, 2018 | $13.05M | -90.6% |
| Q1 FY2018 | Mar 31, 2018 | $12.91M | -90.4% |
| Q4 FY2017 | Dec 31, 2017 | $163.02M | +24.7% |
| Q3 FY2017 | Sep 30, 2017 | $143.25M | +13.3% |
| Q2 FY2017 | Jun 30, 2017 | $138.68M | – |
| Q1 FY2017 | Mar 31, 2017 | $134.30M | – |
| Q4 FY2016 | Dec 31, 2016 | $130.69M | – |
| Q3 FY2016 | Sep 30, 2016 | $126.41M | – |
See a number that looks wrong?